Boothbay Fund Management
BMRN icon

Boothbay Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Boothbay Fund Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,100
Closed -$920K – 2254
2022
Q2 		$920K Sell
11,100
-57,100
-84% -$4.55M 0.02% 859
2022
Q1 		$5.26M Buy
68,200
+57,100
+514% +$4.78M 0.12% 198
2021
Q4 		$981K Buy
+11,100
New +$916K 0.02% 761
2021
Q2 		– Sell
-75
Closed -$566K – 1854
2021
Q1 		$566K Buy
+75
New +$6.13K 0.02% 870
2020
Q3 		– Sell
-47
Closed -$580K – 1049
2020
Q2 		$580K Sell
47
-64
-58% -$6.36K 0.04% 536
2020
Q1 		$938K Buy
+111
New +$9.56K 0.08% 317
2016
Q2 		– Sell
-4,800
Closed -$396K – 533
2016
Q1 		$396K Buy
+4,800
New +$391K 0.1% 309

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Boothbay Fund Management's BMRN Position: Q2 2026 in Review

Boothbay Fund Management increased its BioMarin Pharmaceuticals (BMRN) stake by 89% in Q2 2026, buying an estimated $1.67M and bringing the position to 64,733 shares worth $3.7M. The position accounts for 0.05% of the portfolio, ranked #442.

Boothbay Fund Management first reported a position in BMRN in Q1 2017 and has held it in 13 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Boothbay Fund Management held 64,733 shares of BioMarin Pharmaceuticals worth $3.7M as of Q2 2026.
  • Boothbay Fund Management bought 30,527 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.67M.
  • BioMarin Pharmaceuticals made up 0.05% of Boothbay Fund Management's portfolio in Q2 2026, its #442 holding.
  • Boothbay Fund Management first reported a position in BioMarin Pharmaceuticals in Q1 2017 and has held it in 13 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.